Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDR-934 is a **preclinical cancer program** from **BioDrone Therapeutics** built on the company's **cell-derived vesicle** platform. It is described as a **DNA delivery** therapeutic using a **cell-derived vesicle nanocarrier/extracellular vesicle** approach to transport genetic material into tumor cells or immune cells with the aim of enabling therapeutic gene expression or biologic modulation in oncology. Publicly provided pipeline information identifies the asset as a Smart Drug Delivery program for **cancer**, but does not disclose a specific gene payload, molecular target, manufacturing configuration, route of administration, or branded product name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BDR-934.